LIFECORE BIOMEDICAL, INC. Sales Revenue, Goods, Net (Deprecated 2018-01-31)
LIFECORE BIOMEDICAL, INC. (LFCR) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $149.32 million for the 3-month period ending 2018-02-25, per its 10-Q filed 2018-04-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-04-05
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-02-25 was $149.32M, a 9.34% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-11-26 was $136.46M, a 0.44% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-08-27 was $123.36M, a 6.83% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-05-28 was $127.43M, a 5.83% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $532.26M, a 1.63% decline from fiscal 2016.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $541.10M, a 0.34% increase from fiscal 2015.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $539.26M, a 13.10% increase from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $476.81M, a 7.95% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month as first filed | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-02-25 | $149.32M 10-Q · filed 2018-04-05 | $285.78M derived: sum of 2 quarters · filed 2018-04-05 | $409.14M 10-Q · filed 2018-04-05 | $536.57M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-11-26 | $136.46M 10-Q · filed 2018-01-05 | $259.81M 10-Q · filed 2018-01-05 | $387.24M derived: sum of 3 quarters · filed 2018-03-15 | $523.81M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-08-27 | $123.36M 10-Q · filed 2017-09-28 | $250.79M derived: sum of 2 quarters · filed 2018-03-15 | $387.36M derived: sum of 3 quarters · filed 2018-04-05 | $523.22M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2017-05-28 | $127.43M 10-K/A · filed 2018-03-15 | $264.00M derived: sum of 2 quarters · filed 2018-04-05 | $399.86M derived: sum of 3 quarters · filed 2018-04-05 | $532.26M 10-K/A · filed 2018-03-15 | ||||
| 2017-02-26 | $136.57M 10-Q · filed 2018-04-05 | $272.43M derived: sum of 2 quarters · filed 2018-04-05 | $404.83M 10-Q · filed 2018-04-05 | $540.14M derived: sum of 4 quarters · filed 2018-04-05 | ||||
| 2016-11-27 | $135.87M 10-K/A · filed 2018-03-15 | $268.26M 10-Q · filed 2018-01-05 | $403.57M derived: sum of 3 quarters · filed 2018-03-15 | $533.56M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-08-28 | $132.39M 10-K/A · filed 2018-03-15 | $267.71M derived: sum of 2 quarters · filed 2018-03-15 | $397.70M derived: sum of 3 quarters · filed 2018-03-15 | $538.14M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2016-05-29 | $135.31M 10-K/A · filed 2018-03-15 | $265.30M derived: sum of 2 quarters · filed 2018-03-15 | $405.74M derived: sum of 3 quarters · filed 2018-03-15 | $541.10M 10-K/A · filed 2018-03-15 | ||||
| 2016-02-28 | $129.99M 10-K/A · filed 2018-03-15 | $270.43M derived: sum of 2 quarters · filed 2018-03-15 | $405.79M 10-Q · filed 2017-04-07 | $540.23M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-11-29 | $140.44M 10-K/A · filed 2018-03-15 | $275.80M 10-Q · filed 2017-01-05 | $410.24M derived: sum of 3 quarters · filed 2018-03-15 | $548.77M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-08-30 | $135.35M 10-K/A · filed 2018-03-15 | $269.80M derived: sum of 2 quarters · filed 2018-03-15 | $408.33M derived: sum of 3 quarters · filed 2018-03-15 | $541.00M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2015-05-31 | $134.45M 10-K/A · filed 2018-03-15 | $272.98M derived: sum of 2 quarters · filed 2018-03-15 | $405.64M derived: sum of 3 quarters · filed 2018-03-15 | $539.26M 10-K/A · filed 2018-03-15 | ||||
| 2015-03-01 | $138.53M 10-K/A · filed 2018-03-15 | $271.19M derived: sum of 2 quarters · filed 2018-03-15 | $404.81M 10-Q · filed 2016-03-30 | $525.74M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2014-11-30 | $132.66M 10-K/A · filed 2018-03-15 | $266.28M 10-Q · filed 2016-01-07 | $387.21M derived: sum of 3 quarters · filed 2018-03-15 | $513.59M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2014-08-31 | $133.61M 10-Q · filed 2015-10-01 | $254.54M derived: sum of 2 quarters · filed 2018-03-15 | $380.92M derived: sum of 3 quarters · filed 2018-03-15 | $500.95M derived: sum of 4 quarters · filed 2018-03-15 | ||||
| 2014-05-25 | $120.93M 10-K · filed 2016-08-01 | $247.31M derived: sum of 2 quarters · filed 2016-08-01 | $367.33M derived: sum of 3 quarters · filed 2016-08-01 | $476.81M 10-K · filed 2016-08-01 | ||||
| 2014-02-23 | $126.38M 10-K · filed 2016-08-01 | $126.03M 10-Q · filed 2014-03-28 | $246.41M derived: sum of 2 quarters · filed 2016-08-01 | $355.88M 10-Q · filed 2015-04-02 | $354.51M 10-Q · filed 2014-03-28 | $463.00M derived: sum of 4 quarters · filed 2016-08-01 | ||
| 2013-11-24 | $120.03M 10-K · filed 2016-08-01 | $119.55M 10-Q · filed 2014-01-03 | $229.50M 10-Q · filed 2015-01-09 | $228.48M 10-Q · filed 2014-01-03 | $336.62M derived: sum of 3 quarters · filed 2016-08-01 | $454.49M derived: sum of 4 quarters · filed 2016-08-01 | ||
| 2013-08-25 | $109.48M 10-K · filed 2016-08-01 | $108.93M 10-Q · filed 2013-09-26 | $216.59M derived: sum of 2 quarters · filed 2016-08-01 | $334.46M derived: sum of 3 quarters · filed 2016-08-01 | $449.11M derived: sum of 4 quarters · filed 2016-08-01 | |||
| 2013-05-26 | $107.11M 10-K · filed 2015-07-31 | $224.98M derived: sum of 2 quarters · filed 2015-07-31 | $339.63M derived: sum of 3 quarters · filed 2015-07-31 | $441.71M 10-K · filed 2015-07-31 | $439.57M 10-K · filed 2013-08-07 | |||
| 2013-02-24 | $117.87M 10-K · filed 2015-07-31 | $117.58M 10-Q · filed 2013-04-04 | $232.52M derived: sum of 2 quarters · filed 2015-07-31 | $332.98M 10-Q · filed 2014-03-28 | $417.21M derived: sum of 4 quarters · filed 2015-07-31 | |||
| 2012-11-25 | $114.65M 10-K · filed 2015-07-31 | $114.09M 10-Q · filed 2013-01-04 | $215.39M 10-Q · filed 2014-01-03 | $299.35M derived: sum of 3 quarters · filed 2015-07-31 | $379.41M derived: sum of 4 quarters · filed 2015-07-31 | |||
| 2012-08-26 | $102.07M 10-K · filed 2015-07-31 | $101.30M 10-Q · filed 2012-10-03 | $184.69M derived: sum of 2 quarters · filed 2015-07-31 | $264.75M derived: sum of 3 quarters · filed 2015-07-31 | $346.32M derived: sum of 4 quarters · filed 2015-07-31 | |||
| 2012-05-27 | $82.62M 10-K · filed 2014-08-01 | $162.68M derived: sum of 2 quarters · filed 2014-08-01 | $244.25M derived: sum of 3 quarters · filed 2014-08-01 | $317.55M 10-K · filed 2014-08-01 | $310.27M 10-K · filed 2012-08-08 | |||
| 2012-02-26 | $80.06M 10-K · filed 2014-08-01 | $79.36M 10-Q · filed 2012-03-28 | $161.63M derived: sum of 2 quarters · filed 2014-08-01 | $232.60M 10-Q · filed 2013-04-04 | $229.58M 10-Q · filed 2012-03-28 | $306.80M derived: sum of 4 quarters · filed 2014-08-01 | ||
| 2011-11-27 | $81.57M 10-K · filed 2014-08-01 | $79.35M 10-Q · filed 2012-01-05 | $153.09M 10-Q · filed 2013-01-04 | $226.74M derived: sum of 3 quarters · filed 2014-08-01 | $298.23M derived: sum of 4 quarters · filed 2014-08-01 | |||
| 2011-08-28 | $73.30M 10-K · filed 2014-08-01 | $70.86M 10-Q · filed 2011-10-05 | $145.17M derived: sum of 2 quarters · filed 2014-08-01 | $216.66M derived: sum of 3 quarters · filed 2014-08-01 | $284.38M derived: sum of 4 quarters · filed 2014-08-01 | |||
| 2011-05-29 | $71.87M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $143.36M derived: sum of 2 quarters · filed 2013-08-07 | $211.08M derived: sum of 3 quarters · filed 2013-08-07 | $273.34M 10-K · filed 2013-08-07 | $267.12M 10-K · filed 2012-08-08 | |||
| 2011-02-27 | $71.49M 10-Q · filed 2012-03-28 | $139.21M derived: sum of 2 quarters · filed 2012-03-28 | $201.47M 10-Q · filed 2012-03-28 | |||||
| 2010-11-28 | $67.72M 10-Q · filed 2012-01-05 | $129.98M 10-Q · filed 2012-01-05 | ||||||
| 2010-08-29 | $62.26M 10-Q · filed 2011-10-05 | |||||||
| 2010-05-30 | $228.39M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |